Lymphoma: all 5,624 studies

Page 16 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.

• GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)CompletedNCT01419665Phase 3Results posted
• Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT01415752Phase 2Results posted
• S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell LymphomaCompletedNCT01412879Phase 2Results posted
• Allogeneic Transplant in HIV Patients (BMT CTN 0903)CompletedNCT01410344Phase 2Results posted
• Reduced Intensity Double Umbilical Cord Blood TransplantationCompletedNCT01408563Phase 2Results posted
• Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin LymphomaTerminatedNCT01408043Not applicableResults posted
• BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)CompletedNCT01403948Phase 1Results posted
• E7777 for the Treatment of Patients With Peripheral T-Cell LymphomaCompletedNCT01401530Phase 1Results posted
• Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System LymphomaCompletedNCT01399372Phase 2Results posted
• MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- VincristineCompletedNCT01397825Phase 1/2Results posted
• Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell LymphomaTerminatedNCT01397591Phase 2Results posted
• Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression LevelCompletedNCT01396070Phase 2Results posted
• Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin LymphomaCompletedNCT01393717Phase 2Results posted
• Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin LymphomaCompletedNCT01393106Phase 2Results posted
• Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin LymphomaTerminatedNCT01390584Phase 2Results posted
• Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular LymphomaTerminatedNCT01389076Phase 2Results posted
• A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of WarfarinCompletedNCT01388335Phase 1Results posted
• Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular LymphomaCompletedNCT01381692Phase 1/2Results posted
• A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/LymphomaTerminatedNCT01378871Phase 2Results posted
• Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)TerminatedNCT01370694Phase 1Results posted
• Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01369849Phase 1/2Results posted
• Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell LymphomaCompletedNCT01369784Results posted
• INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With TemsirolimusCompletedNCT01367457Results posted
• Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT01363128Phase 2Results posted
• Safety and Pharmacokinetic Study of RRx-001 in Cancer SubjectsCompletedNCT01359982Phase 1Results posted
• S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell LymphomaCompletedNCT01359592Phase 2Results posted
• Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin LymphomaCompletedNCT01336933Phase 2Results posted
• A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)CompletedNCT01332968Phase 3Results posted
• Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's LymphomasCompletedNCT01329900Phase 2Results posted
• Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT01326728Results posted
• Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsCompletedNCT01326702Phase 1/2Results posted
• Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT01325701Phase 2Results posted
• Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced CancerCompletedNCT01324323Phase 1Results posted
• Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced CancerCompletedNCT01324310Phase 1Results posted
• Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell TransplantCompletedNCT01321541Phase 3Results posted
• Stage I/II Nasal NK Cell LymphomaTerminatedNCT01321008Phase 1/2Results posted
• A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent LymphomaCompletedNCT01317901Phase 1Results posted
• A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological MalignanciesCompletedNCT01315132Phase 2Results posted
• Imexon for Relapsed Follicular and Aggressive LymphomasCompletedNCT01314014Phase 2Results posted
• A Study Of PF-05082566 As A Single Agent And In Combination With RituximabCompletedNCT01307267Phase 1Results posted
• Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade LymphomaCompletedNCT01306643Phase 1/2Results posted
• Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell TransplantCompletedNCT01305200Phase 3Results posted
• A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast CancerTerminatedNCT01296555Phase 1Results posted
• Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)CompletedNCT01294579Phase 2Results posted
• Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)CompletedNCT01292135Phase 1Results posted
• VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell LymphomasTerminatedNCT01289210Phase 1/2Results posted
• A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)TerminatedNCT01287741Phase 3Results posted
• A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and LeukemiasCompletedNCT01287104Phase 1Results posted
• Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell LymphomaTerminatedNCT01282476Phase 2Results posted
• Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin LymphomasCompletedNCT01282424Phase 2Results posted
• Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01281917Phase 2Results posted
• Lenalidomide in HTLV-1 Adult T-Cell LeukemiaCompletedNCT01274533Phase 2Results posted
• Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
• Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic DysfunctionCompletedNCT01273155Phase 1Results posted
• Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell TransplantationCompletedNCT01267812Phase 2Results posted
• Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01261247Phase 2Results posted
• Study of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaCompletedNCT01258998Phase 2Results posted
• Ofatumumab for Minimal Residual Disease (MRD) and Maintenance TherapyTerminatedNCT01258933Phase 2Results posted
• Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)TerminatedNCT01253460Phase 2Results posted
• Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantCompletedNCT01251575Phase 2Results posted
• Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLLTerminatedNCT01241786Phase 2Results posted
• Ofatumumab for Initial Systemic Treatment of Indolent B-cell LymphomaCompletedNCT01239394Phase 2Results posted
• Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)CompletedNCT01236391Phase 2Results posted
• The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS LymphomaTerminatedNCT01235793Phase 2Results posted
• Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular LymphomaCompletedNCT01234766Phase 2Results posted
• Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell LymphomaCompletedNCT01234467Phase 2Results posted
• Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic CancerCompletedNCT01233921Not applicableResults posted
• A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose ChemotherapyTerminatedNCT01232556Phase 3Results posted
• Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001CompletedNCT01226472Phase 2Results posted
• Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade HistologiesCompletedNCT01224821Phase 2Results posted
• Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCTTerminatedNCT01220297Phase 2Results posted
• Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLLCompletedNCT01217749Phase 1/2Results posted
• Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01217229Phase 2Results posted
• Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular LymphomaCompletedNCT01216683Phase 2Results posted
• A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLLTerminatedNCT01203930Phase 2Results posted
• Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic MalignanciesCompletedNCT01203722Phase 1/2Results posted
• Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic TransplantationCompletedNCT01203020Phase 2Results posted
• A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's LymphomaCompletedNCT01200758Phase 3Results posted
• Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing TherapyTerminatedNCT01200589Phase 3Results posted
• Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT01197560Phase 2/3Results posted
• Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell LymphomasCompletedNCT01193842Phase 1/2Results posted
• Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin LymphomaCompletedNCT01190449Phase 2Results posted
• Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis FungoidesTerminatedNCT01187446Phase 1/2Results posted
• Reduced Radiation in Patients With Diffuse Large B-cell LymphomaCompletedNCT01186978Not applicableResults posted
• Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin LymphomaTerminatedNCT01186458Phase 2Results posted
• A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or LymphomaTerminatedNCT01185548Phase 1Results posted
• A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD ChemotherapyCompletedNCT01184885Early Phase 1Results posted
• High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) LymphomaCompletedNCT01182415Phase 2Results posted
• Tandem Auto-Allo Transplant for LymphomaCompletedNCT01181271Phase 2Results posted
• Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell LymphomaCompletedNCT01180049Phase 4Results posted
• Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple MyelomaCompletedNCT01177397Phase 1/2Results posted
• Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLLTerminatedNCT01173679Phase 2Results posted
• Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin LymphomaCompletedNCT01169636Phase 1/2Results posted
• Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT01169532Phase 1Results posted
• Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin LymphomaCompletedNCT01165112Phase 1/2Results posted
• Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 KilogramsCompletedNCT01164475Phase 4Results posted
• Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and LymphomaCompletedNCT01162551Phase 2Results posted
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
• A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular LymphomasCompletedNCT01153971Phase 2Results posted
• Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular LymphomaTerminatedNCT01147393Phase 1/2Results posted

← Lymphoma overview